|Day's Range||3,251.88 - 3,294.38|
|52 Week Range||2,801.14 - 3,865.88|
Eloxx Pharmaceuticals, Inc., (ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders, and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that David P. Snow, Chief Business Officer of Eloxx, will participate in a panel discussion titled “Rare and Orphan Diseases: the biotech industry is making a dent in treatment and diagnosis” at the BIOTECH SHOWCASE™ on Wednesday, January 9, 2019, at the Hilton San Francisco, Union Square. On December 21, 2018, Eloxx was added to the NASDAQ Biotechnology Index (NASDAQ:NBI).
AVROBIO, Inc. (AVRO), (“The Company”) a Phase 2 clinical-stage gene therapy company, today announced that the Company has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ:NBI). The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology and ranked on an annual basis.
CAMBRIDGE, Mass., Dec. 20, 2018 -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of novel cellular.
NEW YORK, Dec. 14, 2018 -- Nasdaq (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective.